



# Medicine Supply Notification

MSN/2026/029

Oxcarbazepine 150mg tablets (Viatris)

Tier 2 – medium impact\*

Date of issue: 03/07/2026

Link: [Medicines Supply Tool](#)

## Summary

- Oxcarbazepine 150mg tablets (Viatris) are out of stock until mid-July 2026.
- Oxcarbazepine 150mg tablets (Trileptal®) remain available and can support increased demand.

## Actions Required

Prescribers should not initiate new patients on oxcarbazepine 150mg tablets (Viatris) until the shortage has resolved. Where patients have insufficient supplies to last until the re-supply date, clinicians should:

- consider prescribing alternative brand of oxcarbazepine 150mg tablets (Trileptal®);
- reassure patient that they are receiving the same treatment, albeit from a different manufacturer, in order to maintain their treatment; and to continue the same dose, and report any side effects or loss of seizure control (or symptom control if being used off-label for trigeminal neuralgia) after the switch; and
- if the above options are not considered appropriate, advice should be sought from specialists on management options.

## Supporting information

### Clinical Information

Oxcarbazepine is licensed for the treatment of partial seizures with or without secondarily generalised tonic clonic seizures, as monotherapy or adjunctive therapy, in adults and in children of 6 years of age and above. The licensed starting dose is 600 mg/day given in 2 divided doses, with doses titrated at approximately weekly intervals to achieve the desired clinical response. Therapeutic effects are seen at doses between 600 mg/day and 2,400 mg/day.

It is a [category 2 antiepileptic drug](#) so the need for continued supply of a particular manufacturer's product should be based on clinical judgement and consultation with patient and/or carer, considering factors such as seizure frequency and treatment history, as well as patient/carer-related factors, including their negative perceptions about alternative products. However, maintaining use of the same brand is dependent on its availability.

### Links to further information

[SmPC Oxcarbazepine](#)

[BNF Oxcarbazepine](#)

[BNF Treatment Summary - Epilepsy](#)

[CKS Epilepsy](#)

## Enquiries

If you have any queries, please contact [DHSCmedicinesupplyteam@dhsc.gov.uk](mailto:DHSCmedicinesupplyteam@dhsc.gov.uk).

\*Classification of Tiers can be found at the following link:

<https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/>